Claims for Patent: 6,159,692

Summary for Patent: 6,159,692

Title:	Method and reagent for inhibiting human immunodeficiency virus replication
Abstract:	An enzymatic nucleic acid molecule which cleaves an immunodeficiency virus RNA in a gene required for viral replication, e.g., the nef or tat gene regions.
Inventor(s):	Draper; Kenneth G. (Boulder, CO), Chowrira; Bharat (Boulder, CO), McSwiggen; James (Boulder, CO), Stinchcomb; Dan T. (Boulder, CO), Thompson; James D. (Boulder, CO)
Assignee:	Ribozyme Pharmaceuticals, Inc. (Boulder, CO)
Application Number:	09/249,215
Patent Claims:	1. An enzymatic nucleic acid molecule that specifically cleaves RNA of the nef gene of human immunodeficiency virus, wherein said enzymatic nucleic acid molecule comprises a substrate binding site and a nucleotide sequence within or surrounding said substrate binding site wherein said nucleotide sequence imparts to said enzymatic nucleic acid molecule activity for the cleavage of said RNA of the nef gene. 2. The enzymatic nucleic acid molecule of claim 1, wherein said substrate binding site is complementary to said RNA of the nef gene. 3. The enzymatic nucleic acid molecule of claim 1, wherein said enzymatic nucleic acid molecule is in a hammerhead motif. 4. The enzymatic nucleic acid molecule of claim 1, wherein said enzymatic nucleic acid molecule is in a hairpin motif. 5. The enzymatic nucleic acid molecule of claim 1, wherein said enzymatic nucleic acid molecule is in a group I intron, group II intron, hepatitis delta virus ribozyme or RNase P M1 RNA motif. 6. The enzymatic nucleic acid molecule of claim 1, wherein said substrate binding site comprises between 12 and 100 nucleotides complementary to said RNA of the nef gene. 7. The enzymatic nucleic acid molecule of claim 1, wherein said substrate binding site comprises between 14 and 24 nucleotides complementary to said RNA of the nef gene. 8. An expression vector comprising nucleic acid sequence encoding one or more enzymatic nucleic acid molecules of claim 1 in a manner that allows expression of said enzymatic nucleic acid molecules. 9. The expression vector of claim 8, wherein said expression vector is a viral vector. 10. The expression vector of claim 9, wherein said viral vector is a retrovirus vector. 11. The enzymatic nucleic acid molecule of claim 1, wherein said enzymatic nucleic acid molecule is chemically synthesized. 12. The enzymatic nucleic acid molecule of claim 1, wherein said enzymatic nucleic acid molecule is in a purified form. 13. The enzymatic nucleic acid molecule of claim 1, wherein said enzymatic nucleic acid molecule is active in the presence of divalent metal ions. 14. The enzymatic nucleic acid molecule of claim 13, wherein said divalent metal ion is magnesium. 15. The enzymatic nucleic acid molecule of claim 1, wherein said enzymatic nucleic acid molecule comprises a sugar modification. 16. The expression vector of claim 8, wherein said nucleic acid sequence encoding said enzymatic nucleic acid molecule is under the control of a mammalian transcription promoter. 17. The expression vector of claim 8, wherein said nucleic acid sequence encoding said enzymatic nucleic acid molecule is under the control of a promoter from a human cytomegalovirus. 18. A method of cleaving the RNA of nef gene comprising the step of contacting said RNA with the enzymatic nucleic acid molecule of claim 1 under conditions suitable for the cleavage of said RNA. 19. A mammalian cell including the enzymatic nucleic acid molecule of claim 1, wherein said mammalian cell is not a living human. 20. The mammalian cell of claim 19, wherein said mammalian cell is a human cell. 21. A mammalian cell including the expression vector of claim 8, wherein said mammalian cell is not a living human. 22. The mammalian cell of claim 21, wherein said mammalian cell is a human cell. 23. The enzymatic nucleic acid molecule of claim 1, wherein said enzymatic nucleic acid molecule comprises a poly A tail. 24. A pharmaceutical composition comprising an enzymatic nucleic acid molecule of claim 1. 25. The enzymatic nucleic acid molecule of claim 1, wherein said enzymatic nucleic acid molecule comprises a 5'-cap. 26. The enzymatic nucleic acid molecule of claim 1, wherein said enzymatic nucleic acid molecule comprises a 3'-cap. 27. The enzymatic nucleic acid molecule of claim 1, wherein said enzymatic nucleic acid molecule is capable of inhibiting propagation of said human immunodeficiency virus.

Details for Patent 6,159,692

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2012-05-14
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2012-05-14
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2012-05-14